- Home
- NBH vs BDTX Comparison
NBH vs BDTX Comparison
Compare NBH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- BDTX
- Stock Information
- Founded
- NBH 2002
- BDTX 2014
- Country
- NBH United States
- BDTX United States
- Employees
- NBH N/A
- BDTX N/A
- Industry
- NBH Finance/Investors Services
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBH Finance
- BDTX Health Care
- Exchange
- NBH Nasdaq
- BDTX Nasdaq
- Market Cap
- NBH 328.2M
- BDTX 323.2M
- IPO Year
- NBH N/A
- BDTX 2020
- Fundamental
- Price
- NBH $11.03
- BDTX $3.31
- Analyst Decision
- NBH
- BDTX Strong Buy
- Analyst Count
- NBH 0
- BDTX 4
- Target Price
- NBH N/A
- BDTX $15.50
- AVG Volume (30 Days)
- NBH 85.9K
- BDTX 932.5K
- Earning Date
- NBH 01-01-0001
- BDTX 11-04-2024
- Dividend Yield
- NBH 4.34%
- BDTX N/A
- EPS Growth
- NBH N/A
- BDTX N/A
- EPS
- NBH 0.12
- BDTX N/A
- Revenue
- NBH N/A
- BDTX N/A
- Revenue This Year
- NBH N/A
- BDTX N/A
- Revenue Next Year
- NBH N/A
- BDTX N/A
- P/E Ratio
- NBH $87.04
- BDTX N/A
- Revenue Growth
- NBH N/A
- BDTX N/A
- 52 Week Low
- NBH $8.75
- BDTX $1.62
- 52 Week High
- NBH $11.01
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- NBH 45.73
- BDTX 33.12
- Support Level
- NBH $11.06
- BDTX $3.13
- Resistance Level
- NBH $11.17
- BDTX $3.42
- Average True Range (ATR)
- NBH 0.08
- BDTX 0.24
- MACD
- NBH -0.01
- BDTX 0.02
- Stochastic Oscillator
- NBH 33.86
- BDTX 20.93
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Intermediate Muni Fund is a closed-end management investment company that invests mainly in municipal securities. It aims to provide common stockholders a high level of current income exempt from Federal income tax.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.